We normally hear of cryogenics and preservation of humans in the movies but now it is a reality. At least for the preservation of cord blood and cord lining. So why do we need to preserve cord blood and lining? Call it biological insurance, a future cure for serious diseases such as leukemia. Stem cell linings apparently possess miracle antidotes and other medical potentials still untapped. Though still not yet totally embraced by the public, Cordlife services has some celebrities raving about it . Read on to understand how this works so far.
Cordlife Medical Philippines Inc (“Cordlife” or the “Company”), a fully owned subsidiary of Cordlife Group Limited, a Singapore Exchange mainboard listed consumer healthcare company catering to the mother and child segment, announced the opening of their newly upgraded stem cell processing and cryopreservation facility at UP-Ayalaland Technohub, Quezon City. This expansion came less than 5 years from the opening of its facility in the country and was mainly driven by the growing number of parents who recognize the value of banking their baby’s stem cells in the country.
The event launch held at Crowne Plaza in Ortigas on November 2014 was hosted by popular DJ Delamar Arias and graced by celebrity moms, actress and beauty queen Lara Quigaman and reporter/journalist Niña Corpuz. Delamar, Lara and Nina all shared their personal experiences of being Cordlife moms themselves.
Also in attendance to underscore Cordlife’s commitment to Filipino parents and their children were Cordlife Group CEO Jeremy Yee, Cordlife Philippines Medical Director Dr. Arvin Faundo, and Cordlife Philippines Director Michael Arnonobal.
The event highlighted the five essentials of mother and child that Cordlife addresses through services. These essentials are security, expertise, investment, bond, and value for life.
With the newly upgraded stem cell facility that can accommodate up to 30,000 cord blood and cord lining units, more parents can enjoy a sense of security when they bank their baby’s stem cells at Cordlife’s state-of-the-art processing and cryopreservation laboratory. Parents who banked with Cordlife can have peace of mind knowing that their baby’s stem cells are kept in a highly secure laboratory that was built to withstand earthquakes of up to magnitude 8, and ward off fire with its fire-retardant walls. Furthermore, the vapour-phased liquid nitrogen cryogenic tanks used to preserve the cord blood and cord lining samples are not dependent on electricity, making them 100% safe and reliable in case of power outages.
Cordlife’s expertise in the stem cell banking arena, is proven not only by being the largest network of cord blood banks in Asia, but also the number of cord blood releases for stem cell transplant and their adherence to the stringent global standards of AABB (formerly known as American Association of Blood Banks). Cordlife Philippines is also the country’s first and only ISO 9001:2008 and Department of Health-registered cord blood and cord lining bank.
“With over 13 years of experience in the industry and as a mainboard-listed healthcare company on the Singapore Exchange, we are in the position to provide long-haul high quality stem cell banking service to parents in the Philippines,” says Jeremy Yee.
In addition to cord blood banking, Cordlife Philippines also offers cord tissue banking service, launched last year. “While cord blood is a rich source of hematopoietic stem cells used to treat blood disorders, cord tissue is a rich source of mesenchymal and epithelial stem cells, both of which are now under extensive clinical study for regenerative medicine and a host of other applications such as stroke, myocardial infarction and diabetes treatment,” according to Dr. Arvin Faundo. “Stem cell therapy is indeed one of the brightest spots in the future of medicine, and families can start investing on this future today with Cordlife,” he adds.
Cordlife emphasized once more their commitment to provide more value for life by being a steadfast partner to parents who wish to bank their baby’s stem cells because of their proven ability to treat Leukemia, Thallasemia and other types of cancers2. “I actively tried to develop our parenting IQ, from how to change a diaper to knowing the many diseases that could threaten my baby’s future. I still remember the sense of relief having found out that we could provide him biological insurance through stem cell banking,” saying Lara Quigaman.
By storing the blood and lining of their baby’s umbilical cord, the first connection between mom and child, Cordlife helps preserve this precious bond. Partnerships are forged with trusted hospitals and research institutes like Duke Medicine research, adding more value to this special mother and child bond.
All these essentials are available to parents as a practical investment for their child’s health. “To help the most number of Filipino families access this important service, Cordlife offers cord blood/cord lining banking for as low as P8,000 per year, and offers flexible payment schemes that are within reach of most families,” says Michael Arnonobal.
ABOUT CORDLIFE MEDICAL PHILIPPINES INC
Cordlife Philippines was officially launched in February 2010 as Philippines’ first and only cord blood processing and cryopreservation facility to better serve the cord blood banking needs of the local market. Registered with the Department of Health, the ISO-certified facility was built in accordance to global gold standards such as the American Association of Blood Banks to give local families peace of mind. In 2013, the Company launched the country’s first and only cord lining banking service, using CellOptima™, a patented technology invented in Singapore that can isolate and expand two types of stem cells from the umbilical cord lining. Cordlife’s 365-day facility is equipped with the world’s most advanced fully automated cord blood processing system, SEPAX-2® and has a storage capacity for 30,000 cord blood units. Cordlife Philippines is a subsidiary of Cordlife Group Limited, a mainboard company listed on the Singapore Exchange.
ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)
Incorporated in May 2001, Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), is a consumer healthcare company catering to the mother and child segment and a leading cord blood and umbilical cord lining banking services provider. Amongst the first private cord blood banks in Asia, Cordlife has established a dominant market leader position in Singapore. Today, it has the larger market share of the only two private cord blood banks in Singapore. In Hong Kong, it is amongst the three market leaders for private cord blood banks. Cordlife completed the acquisition of the cord blood and umbilical cord lining banking businesses and assets in India, the Philippines and Indonesia from Australia-listed Life Corporation Limited (formerly known as Cordlife Limited) in June 2013.
Cordlife, through its collaborative relationships or arrangements with major private hospitals and clinics such as Thomson Medical and Parkway East Hospital, has continued to increase public awareness of its cord blood banking services in Singapore. Overseas, the Group has a 10% direct stake in China Cord Blood Corporation – a top cord blood bank operator in China holding majority shares in the Beijing, Guangdong and Zhejiang Cord Blood Banks, and an approximately 24% share in Shandong Cord Blood Bank. In October 2013, Cordlife also acquired a 19.92% stake, which was subsequently increased to approximately 31.81% in December 2013, in StemLife Berhad. StemLife Berhad is a fully licensed cord blood banking facility with the Ministry of Health Malaysia currently listed on the ACE Market of Bursa Malaysia.
Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy.
Cordlife’s track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2012 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7; Baby & Kid Brands Awards year 2013, “My Favourite Cord Blood Bank” by Hong Kong Economic Times; and Baby Kingdom Top 10 Family Brand Award 2012. In October 2012, Cordlife was awarded the prestigious SIAS Investors’ Choice Awards as runner-up in the “Most Transparent Company Award 2012” New Issues Category. In August 2013, we were presented with Merit Award for the Singapore Corporate Awards 2013, “Best Investor Relations Award”. In November 2013, Cordlife was named the “Most Transparent Company 2013” in the Retail & Household Goods Category and Mainboard Small Caps Category at the 14th SIAS Investors’ Choice Awards.